Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A

As of June 30, 2026, Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A carries a market capitalization of 3.34B, placing it among publicly traded companies globally. Its enterprise value stands at -183.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A has 232.52M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A maintains a current ratio of 18.63, meaning it holds 18.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A recorded 10.12M in income tax expense.

As of the close on October 23, 2026, Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A's stock has declined approximately 26.46% over the past 52 weeks. The 50-day moving average sits at 15.18, while the 200-day moving average is 16.44.

As of June 30, 2026, Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A holds 3.67B in cash and equivalents against 31.16M in total debt, resulting in a net debt position of -333.72M. Total book value stands at 5.35B, with working capital of 4.24B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A paid dividends of 0.10 per share.

Wuhan Easy Diagnosis Biomedicine Co., Ltd. Class A's most recent stock split took place on June 6, 2023 with a 100:149 split ratio.